T1	Participants 38 124	zidovudine (AZT)-treated asymptomatic HIV-infected subjects with 200-500 CD4 cells/mm3
T2	Participants 300 426	zidovudine (AZT)-treated asymptomatic human immunodeficiency virus (HIV)-infected subjects with 200-500 CD4 cells/mm3 at entry
T3	Participants 432 594	352 subjects were prestratified by prior AZT use into stratum I (235 subjects, > 6 months AZT at entry) and stratum II (117 subjects, < or = 6 months AZT at entry
